Drugs / Omega-3-acid ethyl ester 90
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00294216 | Aug 2003 → Jul 2005 | cardiovascular disorder | Pronova BioPharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omega-3-acid ethyl ester 90 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00294216 ↗ |
| Known as | Omacor | “The purpose of this study is to investigate the effect of intake of Omacor (Omega-3-acid ethyl ester 90) 2g/day on specified parameters related to the stability of carotid...” NCT00294216 ↗ |
| Route | Oral | “consume control capsules or n-3 PUFA ethyl ester capsules until surgery” PMID 20542512 ↗ May 2010 |